



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

August 10, 2023

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001
Scrip Code: 533543

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051
Symbol: **BROOKS**

Sub: Outcome of Board Meeting

Ref: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sir/Madam,

This is with reference to the regulation mentioned above:

In continuation of our intimation dated August 2, 2023 and pursuant to Regulation 30 & Regulation 33 and other applicable regulations of the LODR, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Thursday August 10, 2023, has inter alia approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023.

We attach herewith a copy of the approved Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended June 30, 2023 along with the Limited Review Report of the Auditors.

The meeting started at 2:30 PM and concluded at 4.00 P.M.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

(Jai Vaidya)

Company Secretary cum Compliance Officer

Membership No. A42246

Encl.: As Stated Above

SGCO & Co. LLP

Chartered Accountants

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter ended June 30, 2023, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter ended on June 30, 2023. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S G C O & Co. LLP
Chartered Accountants
Firm's Registration No. 112081W/W100184


Suresh Murarka

Partner

Mem.No. 044739

UDIN: 23044739BGUNRN2676.



Place: Mumbai
Date: 10th August, 2023

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in

Mumbai • Delhi

SGCO & Co. LLP

Chartered Accountants

Limited Review Report on Unaudited Consolidated Financial Results for the quarter ended June 30, 2023, of Brooks Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its Jointly controlled entity and associate for the quarter ended June 30, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
- Brooks Laboratories Limited (Parent Company)
 - Brooks Steriscience Limited (Jointly Controlled Entity)
 - Steribrooks Penems Private Limited (Associate Company)



4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in

SGCO & Co. LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of one Jointly Controlled Entity vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial statement include the Group share of net loss of Rs.393.76 results for the quarter ended 30th June 2023, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Jointly controlled entity, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. The consolidated financial statements also includes the Group's share is NIL for the quarter ended June 30, 2023, as considered in the consolidated unaudited financial statements, in respect of one associate (Steribrooks Penems Private Limited) whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management. Our conclusion on the Statement is not modified in respect of the above matters.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration No. 112081W/W100184



Suresh Murarka

Partner

Mem.No. 044739

UDIN: 2304473930 UNR03270



Place: Mumbai

Date: 10th August, 2023

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939


Statements of unaudited Financial Results for the Quarter Ended 30th June 2023

(Rs. In Lakhs)

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1 Income								
Revenue from operations	1,570.27	1,261.41	1,494.28	5,553.80	1,570.27	1,261.41	1,712.36	6,320.46
Other Income	5.48	1.91	4.62	10.72	5.48	1.91	3.41	20.34
Total income	1,575.75	1,263.32	1,498.90	5,564.52	1,575.75	1,263.32	1,715.77	6,340.80
2 Expenses								
(a) Cost of materials consumed	1,066.54	833.55	834.62	3,232.84	1,066.54	833.55	1,449.66	4,154.53
(b) Purchase of Stock in Trade	86.09	58.66	279.09	611.99	86.09	58.66	279.09	487.24
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(54.55)	(71.63)	136.69	200.90	(54.55)	(71.63)	(112.85)	418.45
(d) Employees benefits expenses	277.35	226.22	354.99	1,154.12	277.35	226.22	571.15	1,734.16
(e) Finance Costs	17.11	18.43	15.71	76.67	17.11	18.43	62.29	218.32
(f) Depreciation and amortization expenses	44.09	43.55	42.34	171.74	44.09	43.55	198.21	702.68
(g) Other expenses	192.39	226.54	292.47	935.38	192.39	226.54	385.22	2,167.91
Total Expenses	1,629.02	1,335.32	1,955.91	6,383.64	1,629.02	1,335.32	2,832.77	9,883.29
3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax	(53.27)	(72.00)	(457.01)	(819.12)	(53.27)	(72.00)	(1,117.00)	(3,542.49)
4 Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	(393.76)	(357.85)	-	(330.99)
Profit/(Loss) before Exceptional item and tax	(53.27)	(72.00)	(457.01)	(819.12)	(447.03)	(429.85)	(1,117.00)	(3,873.48)
5 Exceptional items	-	-	-	-	-	-	-	(35.67)
6 Profit/(Loss) from ordinary activities before tax	(53.27)	(72.00)	(457.01)	(819.12)	(447.03)	(429.85)	(1,117.00)	(3,837.81)
7 Tax Expense:								
Deferred Tax Liability / (Assets)(Refer note 7)	-	-	-	-	-	-	(177.25)	(732.40)
MAT credit reversal	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	-	-	-
8 Net Profit/(loss) after tax	(53.27)	(72.00)	(457.01)	(819.12)	(447.03)	(429.85)	(939.75)	(3,105.39)
9 Other Comprehensive Income								
Items That will not be reclassified into Profit or loss								
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	(4.10)	-	(4.10)	-	(4.10)	-	(4.10)
Gain on remeasuring FVTPL financial assets	-	0.81	-	0.81	-	0.81	-	0.81
10 Total Comprehensive income for the period	(53.27)	(75.29)	(457.01)	(822.41)	(447.03)	(433.14)	(939.75)	(3,108.68)
Net Profit attributable to								
Owners of equity	-	-	-	-	-	(429.85)	(690.06)	(2,089.99)
Non Controlling Interest	-	-	-	-	-	-	(249.69)	(1,015.40)
Other Comprehensive Income attributable to :								
Owners of equity	-	-	-	-	-	(3.29)	(690.06)	(3.29)
Non Controlling Interest	-	-	-	-	-	-	(249.69)	-
Total Comprehensive Income attributable to								
Owners of Equity	-	-	-	-	-	(433.14)	(690.06)	(2,093.28)
Non Controlling Interest	-	-	-	-	-	-	(249.69)	(1,015.40)
11 Paid-up equity share capital (Face Value of Rs. 10 each)	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28
12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.	3,207.61	4,030.03	4,030.03	4,030.03	4,925.05	6,278.73	6,278.73	6,278.73
13 Earnings per share (of Rs. 10/- each) (not annualised)								
(a) Basic	(0.22)	(0.30)	(1.85)	(3.33)	(1.81)	(1.75)	(3.80)	(12.58)
(b) Diluted	(0.22)	(0.30)	(1.85)	(3.33)	(1.81)	(1.75)	(3.80)	(12.58)

Notes:

- The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 10th August 2023
- The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- Figures for the quarter ended 31st March 2023 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
- The Board of Directors at its meeting held on July 18, 2023, has inter alia considered and approved the rights issue of 15,43,926 fully paid-up Equity Shares of Rights issue price of Rs.75 per equity share [including a premium of Rs. 65 per Equity Share] for amount aggregating up to Rs. 1,157.94 lakhs . Subsequently, Rights Issue Letter of Offer (LoF) was filed on August 1, 2023 with BSE Limited (BSE), August 2, 2023 with National Stock Exchange of India Limited (NSE) and August 3,2023 with Securities and Exchange Board of India (SEBI) Mumbai - 93



Brooks Laboratories Limited


Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939

- 5 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 6 During the Quarter Ended December 31 2022, the company has lost control over its own subsidiary company Brooks Steriscience Limited(BSL) and the company now jointly controls the entity along with its JV partner and has accounted accordingly subsequent to loss of control. Hence the current year quarter figures are not comparable with previous year quarter figures.
- 7 In the absence of future taxable profit, The Company has not recognised deferred tax asset on its business losses/depreciation in accordance with Ind As 12 " Income taxes"
- 8 The Company operates in one reportable business segment i.e " Pharmaceuticals".
- 9 Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board



Kaushalya Singh
Din : 09244596
Wholetime Director



Place : Baddi

Date : 10th August 2023